AR052677A1 - Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptables - Google Patents

Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptables

Info

Publication number
AR052677A1
AR052677A1 ARP060100732A ARP060100732A AR052677A1 AR 052677 A1 AR052677 A1 AR 052677A1 AR P060100732 A ARP060100732 A AR P060100732A AR P060100732 A ARP060100732 A AR P060100732A AR 052677 A1 AR052677 A1 AR 052677A1
Authority
AR
Argentina
Prior art keywords
acceptable salts
pharmacologically acceptable
racemic form
enantiomeric forms
cpt
Prior art date
Application number
ARP060100732A
Other languages
English (en)
Spanish (es)
Inventor
Fabio Gianessi
Emanuela Tassoni
Maria Ornella Tinti
Roberto Conti
Uomo Natalina Dell
Tiziana Brunetti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR052677A1 publication Critical patent/AR052677A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
ARP060100732A 2005-03-02 2006-02-28 Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptables AR052677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000090A ITRM20050090A1 (it) 2005-03-02 2005-03-02 Derivati dell'acido ammino-butanoico inibitore della cpt.

Publications (1)

Publication Number Publication Date
AR052677A1 true AR052677A1 (es) 2007-03-28

Family

ID=36090946

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100732A AR052677A1 (es) 2005-03-02 2006-02-28 Compuesto en la forma racemica (r,s) o en sus formas enantiomericas r y s y sus sales farmacologicamente aceptables

Country Status (15)

Country Link
US (1) US20080161395A1 (enExample)
EP (1) EP1853556A1 (enExample)
JP (1) JP2008531613A (enExample)
KR (1) KR20070114197A (enExample)
CN (1) CN101133019A (enExample)
AR (1) AR052677A1 (enExample)
AU (1) AU2006220097B2 (enExample)
BR (1) BRPI0607558A2 (enExample)
CA (1) CA2599165A1 (enExample)
EA (1) EA200701868A1 (enExample)
IT (1) ITRM20050090A1 (enExample)
MX (1) MX2007009007A (enExample)
SG (1) SG159569A1 (enExample)
TW (1) TW200640842A (enExample)
WO (1) WO2006092204A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030654A (zh) 2006-10-03 2015-11-11 阿尔尼拉姆医药品有限公司 含脂质的制品
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
CA2677049A1 (en) 2007-08-01 2009-02-05 Sionex Corporation Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
BRPI0911159A2 (pt) * 2008-04-29 2015-10-06 Hoffmann La Roche compostos derivados de ácido 4-dimetilaminobutírico, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por inibidres de cpt2 e uso destes compostos
RU2502727C2 (ru) 2008-04-29 2013-12-27 Ф.Хоффманн-Ля Рош Аг 4-триметиламмониобутираты в качестве ингибиторов срт2
US20230295097A1 (en) * 2020-07-17 2023-09-21 Sanofi Pasteur Lipidic compounds comprising at least one terminal radical of formula -nh-cx-a or -nh-cx-nh-a, compositions containing them and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6822115B2 (en) * 1999-06-30 2004-11-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
CA2680366C (en) 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer

Also Published As

Publication number Publication date
CN101133019A (zh) 2008-02-27
MX2007009007A (es) 2007-09-14
AU2006220097B2 (en) 2011-07-07
KR20070114197A (ko) 2007-11-29
TW200640842A (en) 2006-12-01
EP1853556A1 (en) 2007-11-14
SG159569A1 (en) 2010-03-30
AU2006220097A1 (en) 2006-09-08
CA2599165A1 (en) 2006-09-08
WO2006092204A1 (en) 2006-09-08
ITRM20050090A1 (it) 2006-09-03
EA200701868A1 (ru) 2008-02-28
US20080161395A1 (en) 2008-07-03
BRPI0607558A2 (pt) 2009-09-15
JP2008531613A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
CY1120389T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
CR20120019A (es) Composicion de insulina de accion prolongada
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
ECSP10010526A (es) Compuesto heterociclico
CO6362017A2 (es) Peptidos antivirales terapeuticos
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
MX374694B (es) USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS.
PT2359834T (pt) Tratamento de doentes com hemoglobimúria paroxística noturna por meio de um inibidor de complemento
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
UY32030A (es) &#34;tratamiento para diabetes en pacientes inapropiados para terapia con metformina&#34;
CR11231A (es) Compuestos modulares de sirtuina
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2007002996A1 (es) Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY30835A1 (es) 8-alquinilxantinas y derivados
UY31968A (es) Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal